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MHC Major histocompatibility complex 
Min Minutes 
MM Multiple myeloma 
mRNA Messenger ribonucleic acid 
MSAG Medical Scientific Advisory Group  
mSMART Mayo stratification of Myeloma and Risk Adapted Therapy 
n (sample) number 
N/A Not applicable 
NF-κB Nuclear factor kappa B 
ng Nanograms 
NK cells Natural killer cells 
NT Not available for testing 
nTreg Natural T regulatory cells 
p16 p16INK4a 
p21 p21CIP1/WAF1 
PB Peripheral blood 
PBMC/s Peripheral blood mononuclear cell/s 
PBS Phosphate buffered saline 
PBSC Peripheral blood stem cell 
PCR Polymerase chain reaction 
PD-1 Programmed cell death protein-1 or CD274 
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PI Propidium iodide 
PI3K Phosphoinositide 3-kinase 
PMA Phorbol 12-myristate 13-acetate   
Pom Pomalidomide 
pRb Retinoblastoma tumor suppressor 
PTP Protein tyrosine phosphatase 
PTPN7 Protein tyrosine phosphatase non-receptor type 7 
qPCR Quantitative polymerase chain reaction 
RPAH Royal Prince Alfred Hospital 
RT Room temperature 
SARA SMAD anchor for receptor activation 
SASP Senescence associated secretory phenotype 
SCT Stem cell transplant 
SHP-2 Src homology 2 (SH2) domain containing protein tyrosine 
phosphatase (PTP) 
SM Smouldering myeloma 
SMAD Homologs of the Caenorhabditis elegans protein SMA and the 
Drosophilia protein, mothers against decapentaplegic (MAD)  
SPE  Serum protein electrophoresis 
STAT3 Signal transducer and activator of transcription 
T cells T lymphocytes 
TCR T cell receptor 
TdT Terminal deoxynucleotidyl transferase 
TGF-β Transforming growth factor β 
Th T helper cell 
T-LGL T-large granulocytic l 
TNF Tumour necrosis factor 
Treg T regulatory cell 
T/S  Telomeric DNA quantity/single copy gene DNA quantity 
U International Units 
U&E Urea and electrolytes 
UV Ultraviolet 
V Variable 
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Vβ Beta chain of the variable region (of the TCR) 
WHO World Health Organisation 
WM Waldenström macroglobulinaemia 
ZAP-70 ζ-chain associated protein kinase of 70kDa 
α Alpha 
β Beta 
γ Gamma 
δ Delta 
Κ Kappa 
λ Lambda 
°C Centrigrade (degrees Celsius) 
μL Microlitres 
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ABSTRACT 
 
Multiple myeloma is a cancer involving malignant plasma cells in the bone 
marrow. Despite advances in therapy, relapse is inevitable due to residual 
disease and myeloma remains incurable. New therapies are required to remove 
residual disease and maintain long term survival. Expanded clones of cytotoxic 
T cells have been detected in myeloma and their presence is associated with 
improved survival, suggesting a role in anti-tumour immunity. However, these 
cells are dysfunctional as they do not proliferate. Thus, tumour-induced 
dysfunction of T cell clones may be a tumour evasion mechanism that 
contributes to immune escape. The primary aim of this thesis was to elucidate 
the mechanism/s responsible for the observed dysfunction of these T cell 
clones, which may allow future development and implementation of novel 
strategies to restore clonal T cell function. 
 
T cell clones were detected in 75% of a new cohort of myeloma patients 
(n=103) and their presence was associated with an improved survival, despite 
being non-proliferative. T cell clones were present in 100% of long term 
survivors of myeloma, providing further evidence that these cells prolong 
survival. In contrast, T cell clones from 10 year survivors were proliferative. 
Phospho-flow technology was used to investigate the differences in cell 
signalling pathways between T cell clones of 10 year and non-10 year survivors. 
The dysfunction in these cells was related to the upregulation of the SMAD 
pathway, promoting T cell inactivation and downregulation of the ERK pathway, 
which blocks proliferation of T cells.   
 
Classification of T cell clones into an anergic, exhausted or senescence 
phenotype was carried out to determine if dysfunction is reversible, since 
reversal of dysfunction is phenotype dependent. The cells exhibited a 
senescent secretory effector phenotype: KLRG-1+/CD57+/CD160+/CD28- with 
normal telomere lengths for age, suggesting telomere-independent senescence. 
Importantly, the results demonstrate that dysfunction is potentially reversible. 
The p38-MAPK, p16 and p21 signaling pathways, which are known to induce 
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senescence were not upregulated. However, elevated telomerase levels may 
explain how senescent T cells maintain normal telomere lengths.   
 
This thesis expands our understanding of the biology and clinical significance of 
T cell clones. It is the first to describe the dysfunction of T cell clones as 
telomere independent senescence, which is potentially reversible. Additionally, 
it has identified two novel mechanisms by which tumour cells induce 
dysfunction in T cell clones. These findings have implications for reversing 
tumour-induced dysfunction of T cell clones in patients with myeloma.
